ProfileGDS5678 / 1418634_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 91% 89% 92% 91% 85% 88% 90% 88% 90% 91% 91% 89% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.1859490
GSM967853U87-EV human glioblastoma xenograft - Control 27.4758591
GSM967854U87-EV human glioblastoma xenograft - Control 37.1031689
GSM967855U87-EV human glioblastoma xenograft - Control 47.8203292
GSM967856U87-EV human glioblastoma xenograft - Control 57.4900691
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1231885
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7257888
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.089490
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.766688
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.2405990
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.3012291
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.5241391
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.045589
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3438291